November 10th 2023
The 3-year PFS rate for patients with MCL was 94%, and the OS rate was 97%
November 6th 2023
Data from a phase 2 trial support lenalidomide plus rituximab as a novel treatment strategy for patients with previously untreated mantle cell lymphoma.
October 11th 2023
CAR-HEMATOTOX scores may enable risk stratification of patients with mantle cell lymphoma prior to treatment with brexucabtagene autoleucel.
October 6th 2023
Complete responses in patients with pretreated relapsed/refractory mantle cell lymphoma treated with glofitamab appear to be early and enduring.
September 19th 2023
Objective response rate appears to be numerically higher for patients receiving zanubrutinib for relapsed/refractory mantle cell lymphoma in the second-line setting than in later lines of treatment.
Stem Cell Transplant Yields Enduring Disease Control in TP53-Mutated MCL
Allogeneic stem cell transplant should be strongly considered as a treatment for patients with mantle cell lymphoma who are adequately fit, according to Thomas E. Lew.
Avyakta Kallam, MD, on the Future of Mantle Cell Lymphoma
Avyakta Kallam, MBBS, gave a look as to why she decided to compile a comprehensive review in mantle cell lymphoma.
Current Treatments in Mantle Cell Lymphoma
Avyakta Kallam, MBBS and Julie Vose MD, MBA, review available treatment options for patients with mantle cell lymphoma.
Data Suggest High Health Care Costs, Poor OS in Elderly MCL Population
Findings from a real-world study suggest the importance of novel agents for improving efficacy outcomes and tolerability in elderly patients with mantle cell lymphoma.
Serum CD163 May be Predictive of Outcomes in Mantle Cell Lymphoma
Levels of soluble CD163 appear to be higher in those with p53 abnormalities, elevated lactate dehydrogenase, and low hemoglobin in a study cohort of patients with mantle cell lymphoma.
Umbralisib Triplet May Benefit BTK-Naïve Population With R/R MCL
Umbralisib in combination with ublituximab and venetoclax appears tolerable and yields responses in a small cohort of patients with mantle cell lymphoma.
Shorter Diagnosis to Treatment Period Correlates With Worse Survival In MCL
Patients with mantle cell lymphoma who undergo a shorter diagnosis to treatment interval also have worse clinical and disease characteristics on average than those with a longer interval.
Liso-Cel Shows Durable Responses in R/R Mantle Cell Lymphoma
Treatment with liso-cel produces low rates of severe cytokine release syndrome in relapsed/refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.
Pirtobrutinib Yields Sustained Efficacy in R/R Mantle Cell Lymphoma
The non-covalent BTK inhibitor shows an encouraging duration of response in patients with heavily pretreated, relapsed/refractory mantle cell lymphoma, according to data.
Acalabrutinib Combo Shows Promising Outcomes in Mantle Cell Lymphoma
Overall survival rates at 12 and 36 months appear to favor the addition of acalabrutinib to bendamustine and rituximab in the treatment of those with mantle cell lymphoma in a phase 1b trial.
Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma
Rituximab plus bendamustine and cytarabine continues to show clinical efficacy and favorable outcomes in a population of elderly patients with mantle cell lymphoma.
Liso-cel Yields Significant Responses in R/R Mantle Cell Lymphoma
Liso-cel produces no new safety signals in relapsed or refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.
FDA Requests Withdrawal of Ibrutinib in US for Lymphoma Indications
Primary outcome data from phase 3 confirmatory studies evaluating ibrutinib in mantle cell lymphoma and marginal zone lymphoma are insufficient to support conversion to full FDA approval in these indications.
Real-World Data Highlight Need for Clinically Practical MCL Therapies
Retrospective data encourage further exploration of non-ASCT regimens in younger patients with mantle cell lymphoma, while maintenance rituximab should be considered following first-line therapy with bendamustine plus rituximab.
Acalabrutinib Receives Chinese Approval in Mantle Cell Lymphoma
Findings from 2 clinical trials support the approval of acalabrutinib as a treatment for patients with mantle cell lymphoma in China.
MCL Has More Hospitalization/Infections Regardless of Transplant/Intensity
Investigators indicate that although avoiding efficient mantle cell lymphoma treatment due to late effects may seem okay, most long-term health care needs are disease related in patients up to 70 years.
Venetoclax Yields Positive ORR But Poor PFS in R/R Mantle Cell Lymphoma
Findings from a multicenter analysis indicate that tumor lysis syndrome is a notable risk in patients with mantle cell lymphoma receiving treatment with venetoclax.
Brexu-cel Yields Consistent Efficacy in R/R Mantle Cell Lymphoma in SOC Setting
Prior exposure to recent bendamustine and having tumor-intrinsic features were associated with inferior efficacy outcomes following treatment with brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma.
Bendamustine/Rituximab Appears Tolerable in Geriatric Mantle Cell Lymphoma
Real-world findings from an observational study indicate that bendamustine plus rituximab appears to be well tolerated by elderly patients with transplant-ineligible mantle cell lymphoma and indolent non-Hodgkin lymphoma.
FDA Grants Accelerated Approval to Pirtobrutinib for Relapsed/Refractory MCL
The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.
FDA Grants Orphan Drug Designation to Investigational Drug for Mantle Cell Lymphoma
LP-284, which now has orphan drug designation from the FDA for mantle cell lymphoma, yielded positive preclinical data at the 2022 American Society of Hematology Annual Meeting and Exposition.
Zandelisib/Zanubrutinib Elicit High Response Rate in Mantle Cell Lymphoma and Follicular Lymphoma
In a population of patients with patients with mantle cell lymphoma and follicular lymphoma, zandelisib plus zanubrutinib did not increase the rate or severity of class-related adverse effects.
Addition of Lenalidomide to Rituximab Consolidation Misses PFS End Point in Mantle Cell Lymphoma
Lenalidomide plus rituximab consolidation therapy prior to bendamustine/rituximab induction did not significantly improve progression-free survival in patients with mantle cell lymphoma in the phase 2 NCTN E1411 trial.
Time-Limited Ibrutinib Plus CAR-T Cell Therapy May Improve Outcomes in Relapsed/Refractory MCL
Treatment with the BTK inhibitor ibrutinib plus the CAR-T cell therapy tisagenlecleucel produced a high rate of durable responses in patients with relapsed/refractory mantle cell lymphoma after they stopped treatment at 6 months, according to early data from the TARMAC trial.
Acalabrutinib May Be an Effective Addition to Lenalidomide/Rituximab Regimen in Frontline MCL
Acalabrutinib produced promising response rates in combination with lenalidomide and rituximab in previously untreated patients with mantle cell lymphoma.
Addition of Ibrutinib to CRT/ASCT Appears to Improve Outcomes for MCL
Treatment with induction and maintenance ibrutinib combined with chemoimmunotherapy and autologous stem cell transplant resulted in statistically significantly improved outcomes in a younger population with mantle cell lymphoma.
Zilovertamab Plus Ibrutinib Yields Promising Responses and PFS in MCL and CLL
Ziolvertamab and Ibrutinib combination therapy demonstrated an overall response rate of 89.3% and 91.2% in patients with mantle cell lymphoma and chronic lymphocytic leukemia, respectively.
Fixed-Duration Glofitamab Regimen Elicits Early, Durable Responses in Heavily Pretreated Patients with Relapsed/Refractory Mantle Cell Lymphoma
The use of a fixed-duration regimen of glofitamab several days after pretreatment with obinutuzumab was associated with high complete responses among a group of heavily pretreated patients with relapsed or refractory mantle cell lymphoma.
Real-World Data Support the Use of Ibrutinib/Rituximab in Advanced Non-Hodgkin Lymphoma Subtype
Real-world data show effective outcomes following ibrutinib and rituximab treatment in patients with relapsed/refractory mantle cell lymphoma with bone marrow involvement.
Andre H. Goy, MD, on Unresolved Questions in Mantle Cell Lymphoma
Andre H. Goy, MD, discussed the most pressing unresolved questions in the current treatment of MCL in an interview with the journal ONCOLOGY.
2 Clarke Drive Cranbury, NJ 08512